Market Cap 10.13M
Revenue (ttm) 37.32M
Net Income (ttm) -17.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -47.59%
Debt to Equity Ratio -1.73
Volume 192,500
Avg Vol 432,068
Day's Range N/A - N/A
Shares Out 11.65M
Stochastic %K 50%
Beta 0.61
Analysts Strong Sell
Price Target $6.00

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatmen...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 245 1325
Address:
120 Presidential Way, Suite 330, Woburn, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 21 at 12:52 AM
$BFRI RSI: 37.50, MACD: 0.0009 Vol: 0.03, MA20: 0.88, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LION86
LION86 Mar. 20 at 12:21 AM
$BFRI Im here since 12/21/21, and I can say for sure that it is the best earnings reports… But, still the price doesn’t move yet… it’s crazy!
0 · Reply
ivo98
ivo98 Mar. 19 at 2:46 PM
$BFRI 17.1 mlj Q4 --> they may have withheld Q3 revenues to embellish Q4. The total 12% annual increase is misleading due the two times 5% price increase per Ameluz unit. 5% implemented Oktober 2024 5% price increase Ameluz Q2 2025.
2 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 19 at 2:33 PM
$BFRI Q4 '25 Earnings Results & Recap Biofrontera expects full annualized benefits from its strategic transformation in 2026, moving toward sustained profitability and cash flow breakeven. The company also has a PDUFA date for sBCC in September 2026.
0 · Reply
Stereo
Stereo Mar. 19 at 2:07 PM
$BFRI Based on the 8K this would raise their EPS to $0.48 for the quarter.
0 · Reply
Stockseeking
Stockseeking Mar. 17 at 2:45 PM
$BFRI It is a high risk and high reward investment. Considering the extremely low price and the potential several folds of return, it is worth to take some risks
0 · Reply
Stockseeking
Stockseeking Mar. 16 at 6:30 PM
$BFRI the same product in a larger pharma can make more revenue with the much larger sale force
0 · Reply
ivo98
ivo98 Mar. 16 at 12:51 PM
$BFRI @Stereo it's a cashburning company. Less revenues from Ameluz sales 2025 versus 2024. 17 mlj from latest news is with sales and license from Xepi.
1 · Reply
LION86
LION86 Mar. 15 at 10:58 PM
$BFRI 3+ this Week after earnings đź’Ş
0 · Reply
Stereo
Stereo Mar. 15 at 7:49 PM
$BFRI "Large companies frequently acquire smaller companies after patent disputes, with studies indicating that an initial patent lawsuit increases the likelihood of a subsequent acquisition attempt by approximately 40% in certain industries. This "sue-and-acquire" strategy is particularly common in patent-intensive fields like pharmaceuticals and high-tech, where it serves as a way to resolve legal disputes, gain control of technology, and neutralize competition."
1 · Reply
Latest News on BFRI
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 21 at 12:52 AM
$BFRI RSI: 37.50, MACD: 0.0009 Vol: 0.03, MA20: 0.88, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LION86
LION86 Mar. 20 at 12:21 AM
$BFRI Im here since 12/21/21, and I can say for sure that it is the best earnings reports… But, still the price doesn’t move yet… it’s crazy!
0 · Reply
ivo98
ivo98 Mar. 19 at 2:46 PM
$BFRI 17.1 mlj Q4 --> they may have withheld Q3 revenues to embellish Q4. The total 12% annual increase is misleading due the two times 5% price increase per Ameluz unit. 5% implemented Oktober 2024 5% price increase Ameluz Q2 2025.
2 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 19 at 2:33 PM
$BFRI Q4 '25 Earnings Results & Recap Biofrontera expects full annualized benefits from its strategic transformation in 2026, moving toward sustained profitability and cash flow breakeven. The company also has a PDUFA date for sBCC in September 2026.
0 · Reply
Stereo
Stereo Mar. 19 at 2:07 PM
$BFRI Based on the 8K this would raise their EPS to $0.48 for the quarter.
0 · Reply
Stockseeking
Stockseeking Mar. 17 at 2:45 PM
$BFRI It is a high risk and high reward investment. Considering the extremely low price and the potential several folds of return, it is worth to take some risks
0 · Reply
Stockseeking
Stockseeking Mar. 16 at 6:30 PM
$BFRI the same product in a larger pharma can make more revenue with the much larger sale force
0 · Reply
ivo98
ivo98 Mar. 16 at 12:51 PM
$BFRI @Stereo it's a cashburning company. Less revenues from Ameluz sales 2025 versus 2024. 17 mlj from latest news is with sales and license from Xepi.
1 · Reply
LION86
LION86 Mar. 15 at 10:58 PM
$BFRI 3+ this Week after earnings đź’Ş
0 · Reply
Stereo
Stereo Mar. 15 at 7:49 PM
$BFRI "Large companies frequently acquire smaller companies after patent disputes, with studies indicating that an initial patent lawsuit increases the likelihood of a subsequent acquisition attempt by approximately 40% in certain industries. This "sue-and-acquire" strategy is particularly common in patent-intensive fields like pharmaceuticals and high-tech, where it serves as a way to resolve legal disputes, gain control of technology, and neutralize competition."
1 · Reply
Malaazar
Malaazar Mar. 12 at 9:15 PM
$BFRI LOL folks would rather play with this then learn Liq levs of spy. Gamblers paradise
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 10 at 5:12 PM
$BFRI I want it for pdufa in September but not with the cash level it has. 👎
0 · Reply
Tonyboner
Tonyboner Mar. 10 at 10:33 AM
$BFRI Looking for a raise in the next week or so, they are out of cash !
0 · Reply
Stereo
Stereo Mar. 9 at 7:03 PM
$BFRI I guess they are really going to make us wait for the litigation to end this month or the PDUFA in September. September to December timeframe is looking more and more likely for our move.
0 · Reply
MrTicker
MrTicker Mar. 9 at 1:16 PM
$BFRI Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris GLOBENEWSWIRE 8:15 AM ET 3/9/2026
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 4 at 2:21 AM
$BFRI RSI: 62.55, MACD: 0.0143 Vol: 0.05, MA20: 0.86, MA50: 0.84 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SaTwits
SaTwits Feb. 28 at 3:36 AM
$BFRI starter postion is okay, wait for confirmed breakout.
0 · Reply
mmtiddy
mmtiddy Feb. 26 at 5:19 AM
$BFRI Wow, I got looped in because of their PDUFA data in September, but found out this company actually has products, and they are doing decent revenue Why is their market cap so low? It’s 1/3 of their annual revenue
3 · Reply
Stereo
Stereo Feb. 25 at 10:18 PM
$BFRI Sun Pharma just buy us out already. https://data.uspto.gov/ptab/trials/decisions/details/IPR2024-01312/171296810/17942353/decision
0 · Reply
mmtiddy
mmtiddy Feb. 25 at 2:44 PM
$BFRI I bought
0 · Reply
forbsee15
forbsee15 Feb. 23 at 9:37 PM
$BFRI solid finish to the day
0 · Reply
Stockseeking
Stockseeking Feb. 23 at 8:42 PM
$BFRI expect an offer since cash in Sept was only 3.4m
1 · Reply